William Blair Investment Management LLC Buys Shares of 172,181 ICU Medical, Inc. $ICUI

William Blair Investment Management LLC purchased a new position in shares of ICU Medical, Inc. (NASDAQ:ICUI) during the second quarter, Holdings Channel.com reports. The fund purchased 172,181 shares of the medical instruments supplier’s stock, valued at approximately $25,242,000.

Several other hedge funds have also made changes to their positions in ICUI. Allworth Financial LP purchased a new position in shares of ICU Medical in the second quarter valued at approximately $26,000. Hilton Head Capital Partners LLC acquired a new stake in ICU Medical during the 4th quarter worth approximately $32,000. Covestor Ltd lifted its holdings in ICU Medical by 22.1% during the 4th quarter. Covestor Ltd now owns 696 shares of the medical instruments supplier’s stock worth $99,000 after buying an additional 126 shares in the last quarter. Strs Ohio boosted its position in ICU Medical by 60.0% in the 4th quarter. Strs Ohio now owns 800 shares of the medical instruments supplier’s stock valued at $114,000 after buying an additional 300 shares during the period. Finally, Rockefeller Capital Management L.P. boosted its position in ICU Medical by 21.6% in the 4th quarter. Rockefeller Capital Management L.P. now owns 823 shares of the medical instruments supplier’s stock valued at $117,000 after buying an additional 146 shares during the period. Institutional investors and hedge funds own 96.10% of the company’s stock.

Wall Street Analyst Weigh In

A number of research firms have recently weighed in on ICUI. Weiss Ratings raised ICU Medical from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Thursday, July 23rd. KeyCorp lifted their target price on ICU Medical from $164.00 to $182.00 and gave the company an “overweight” rating in a report on Tuesday, July 21st. Needham & Company LLC boosted their target price on ICU Medical from $165.00 to $187.00 and gave the stock a “buy” rating in a research note on Friday, August 7th. Raymond James Financial restated a “strong-buy” rating and set a $200.00 price target on shares of ICU Medical in a report on Friday, August 7th. Finally, BTIG Research increased their price target on ICU Medical from $170.00 to $200.00 and gave the company a “buy” rating in a research report on Friday, August 7th. Two investment analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating and three have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, ICU Medical presently has a consensus rating of “Moderate Buy” and an average target price of $192.80.

Insider Activity at ICU Medical

In other news, COO Christian B. Voigtlander sold 8,929 shares of the company’s stock in a transaction on Tuesday, August 11th. The shares were sold at an average price of $182.93, for a total value of $1,633,381.97. Following the completion of the transaction, the chief operating officer owned 37,377 shares in the company, valued at approximately $6,837,374.61. This represents a 19.28% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, insider Ben Sousa sold 2,250 shares of the company’s stock in a transaction on Wednesday, August 12th. The shares were sold at an average price of $178.32, for a total transaction of $401,220.00. Following the completion of the transaction, the insider owned 3,076 shares of the company’s stock, valued at approximately $548,512.32. The trade was a 42.25% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 16,974 shares of company stock worth $3,085,844 over the last 90 days. 2.10% of the stock is owned by corporate insiders.

ICU Medical Price Performance

Shares of NASDAQ ICUI opened at $182.84 on Friday. The stock’s 50-day simple moving average is $160.85 and its 200-day simple moving average is $143.13. The firm has a market capitalization of $4.57 billion, a PE ratio of 154.95, a price-to-earnings-growth ratio of 2.31 and a beta of 0.74. ICU Medical, Inc. has a fifty-two week low of $112.50 and a fifty-two week high of $192.85. The company has a debt-to-equity ratio of 0.56, a quick ratio of 1.21 and a current ratio of 2.43.

ICU Medical (NASDAQ:ICUI) last announced its quarterly earnings results on Thursday, August 6th. The medical instruments supplier reported $2.37 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.91 by $0.46. The firm had revenue of $547.88 million during the quarter, compared to the consensus estimate of $533.44 million. ICU Medical had a return on equity of 7.91% and a net margin of 1.39%.The firm’s quarterly revenue was up .5% compared to the same quarter last year. During the same period in the prior year, the company posted $2.10 earnings per share. ICU Medical has set its FY 2026 guidance at 8.600-9.000 EPS. As a group, equities research analysts forecast that ICU Medical, Inc. will post 7.19 EPS for the current fiscal year.

ICU Medical Company Profile

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.